Vijayakumar S, Chen GT. Implementation of three dimensional conformal radiation therapy: prospects, opportunities, and challenges. Int J Radiat Oncol Biol Phys. 1995;33(5):979–83.
CAS PubMed Article Google Scholar
Pirzkall A, Carol M, Lohr F, Höss A, Wannenmacher M, Debus J. Comparison of intensity-modulated radiotherapy with conventional conformal radiotherapy for complex-shaped tumors. Int J Radiat Oncol Biol Phys. 2000;48(5):1371–80.
CAS PubMed Article Google Scholar
Chun SG, Hu C, Choy H, Komaki RU, Timmerman RD, Schild SE, Bogart JA, Dobelbower MC, Bosch W, Galvin JM, Kavadi VS, Narayan S, Iyengar P, Robinson CG, Wynn RB, Raben A, Augspurger ME, MacRae RM, Paulus R, Bradley JD. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial. J Clin Oncol. 2017;35(1):56–62.
Murakami YM, Kamima T, Abo N, Takahashi T, Kaneko M, Nakano M, Matsubayashi F, Harada A, Taguchi S, Hashimoto T, Oguchi M, Yoshioka Y. Dosimetric comparison between 3D conformal radiation therapy plus electron boost and simultaneous integrated boost volumetric modulated arc therapy for left-sided breast cancer patients with a potential risk of radiation-induced cardiac toxicity. International Journal of Radiation Oncology*Biology*Physics. 2021;111(3):e525–6.
Maraldo MV, Specht L. A decade of comparative dose planning studies for early-stage Hodgkin lymphoma: what can we learn? Int J Radiat Oncol Biol Phys. 2014;90(5):1126–35.
Paganetti H, Kooy H. Proton radiation in the management of localized cancer. Expert Rev Med Devices. 2010;7(2):275–85.
CAS PubMed Article Google Scholar
Paganetti H, Grassberger C, Sharp GC. Physics of particle beam and hypofractionated beam delivery in NSCLC. Semin Radiat Oncol. 2021;31(2):162–9.
PubMed PubMed Central Article Google Scholar
Kearney M, Keys M, Faivre-Finn C, Wang Z, Aznar MC, Duane F. Exposure of the heart in lung cancer radiation therapy: a systematic review of heart doses published during 2013 to 2020. Radiother Oncol. 2022;172:118–25.
Lin SH, Hobbs BP, Verma V, Tidwell RS, Smith GL, Lei X, Corsini EM, Mok I, Wei X, Yao L, Wang X, Komaki RU, Chang JY, Chun SG, Jeter MD, Swisher SG, Ajani JA, Blum-Murphy M, Vaporciyan AA, et al. Randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer. J Clin Oncol. 2020;38(14):1569–79.
CAS PubMed PubMed Central Article Google Scholar
Maraldo MV, Brodin NP, Aznar MC, Vogelius IR, Munck af Rosenschöld P, Petersen PM, Specht L. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Ann Oncol. 2013;24(8):2113–8.
CAS PubMed Article Google Scholar
Farsad M. FDG PET/CT in the staging of lung cancer. Curr Radiopharm. 2020;13(3):195–203.
CAS PubMed PubMed Central Article Google Scholar
Betancourt-Cuellar SL, Benveniste MFK, Palacio DP, Hofstetter WL. Esophageal cancer: tumor-node-metastasis staging. Radiol Clin North Am. 2021;59(2):219–29.
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance, Australasian Leukaemia and Lymphoma Group, Eastern Cooperative Oncology Group, European Mantle Cell Lymphoma Consortium, Italian Lymphoma Foundation, European Organisation for Research, Treatment of Cancer/Dutch Hemato-Oncology Group, Grupo Español de Médula Ósea, German High-Grade Lymphoma Study Group, German Hodgkin's Study Group, Japanese Lymphorra Study Group, Lymphoma Study Association, NCIC Clinical Trials Group, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–68.
PubMed PubMed Central Article Google Scholar
Specht L, Yahalom J, Illidge T, Berthelsen AK, Constine LS, Eich HT, Girinsky T, Hoppe RT, Mauch P, Mikhaeel NG, Ng A, ILROG. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89(4):854–62.
Geiger GA, Kim MB, Xanthopoulos EP, Pryma DA, Grover S, Plastaras JP, Langer CJ, Simone CB II, Rengan R. Stage migration in planning PET/CT scans in patients due to receive radiotherapy for non-small-cell lung cancer. Clin Lung Cancer. 2014;15(1):79–85.
Bergom C, Bradley JA, Ng AK, Samson P, Robinson C, Lopez-Mattei J, Mitchell JD. Past, present, and future of radiation-induced cardiotoxicity: refinements in targeting, surveillance, and risk stratification. JACC CardioOncol. 2021;3(3):343–59.
PubMed PubMed Central Article Google Scholar
Paoletti L, Ceccarelli C, Menichelli C, Aristei C, Borghesi S, Tucci E, Bastiani P, Cozzi S. Special stereotactic radiotherapy techniques: procedures and equipment for treatment simulation and dose delivery. Rep Pract Oncol Radiother. 2022;27(1):1–9.
PubMed PubMed Central Article Google Scholar
Bergom C, Currey A, Desai N, Tai A, Strauss JB. Deep inspiration breath hold: techniques and advantages for cardiac sparing during breast cancer irradiation. Front Oncol. 2018;8:87.
PubMed PubMed Central Article Google Scholar
Desai N, Currey A, Kelly T, Bergom C. Nationwide trends in heart-sparing techniques utilized in radiation therapy for breast cancer. Adv Radiat Oncol. 2019;4(2):246–52.
PubMed PubMed Central Article Google Scholar
Aznar MC, Maraldo MV, Schut DA, Lundemann M, Brodin NP, Vogelius IR, Berthelsen AK, Specht L, Petersen PM. Minimizing late effects for patients with mediastinal Hodgkin lymphoma: deep inspiration breath-hold, IMRT, or both? Int J Radiat Oncol Biol Phys. 2015;92(1):169–74.
Feng M, Moran JM, Koelling T, Chughtai A, Chan JL, Freedman L, Hayman JA, Jagsi R, Jolly S, Larouere J, Soriano J, Marsh R, Pierce LJ. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2011;79(1):10–8.
Duane F, Aznar MC, Bartlett F, Cutter DJ, Darby SC, Jagsi R, Lorenzen EL, McArdle O, McGale P, Myerson S, Rahimi K, Vivekanandan S, Warren S, Taylor CW. A cardiac contouring atlas for radiotherapy. Radiother Oncol. 2017;122(3):416–22.
PubMed PubMed Central Article Google Scholar
Milo MLH, Offersen BV, Bechmann T, Diederichsen ACP, Hansen CR, Holtved E, Josipovic M, Lörincz T, Maraldo MV, Nielsen MH, Nordsmark M, Nyström PW, Pøhl M, Rose HK, Schytte T, Yates ES, Lorenzen EL. Delineation of whole heart and substructures in thoracic radiation therapy: national guidelines and contouring atlas by the Danish Multidisciplinary Cancer Groups. Radiother Oncol. 2020;150:121–7.
Atkins KM, Rawal B, Chaunzwa TL, Lamba N, Bitterman DS, Williams CL, Kozono DE, Baldini EH, Chen AB, Nguyen PL, D’Amico AV, Nohria A, Hoffmann U, Aerts HJWL, Mak RH. Cardiac radiation dose, cardiac disease, and mortality in patients with lung cancer. J Am Coll Cardiol. 2019;73(23):2976–87 In a cohort of over 700 patients with locally advanced non-small cell lung cancer treated with thoracic radiotherapy, mean heart dose was significantly associated with the development of future major adverse cardiac events, and all cause mortality in patients without existing coronary heart disease. This supports the need for more stringent avoidance of high cardiac dose in this patient population.
Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R, Rahimi K, Taylor C, Hall P. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987–98.
CAS PubMed Article Google Scholar
van Nimwegen FASM, Cutter DJ, Janus CP, Krol AD, Hauptmann M, Kooijman K, Roesink J, van der Maazen R, Darby SC, Aleman BM, van Leeuwen FE. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol. 2016;34(3):235–43.
PubMed Article CAS Google Scholar
Piroth MD, Baumann R, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Hehr T, Krug D, Röser A, Sedlmayer F, Souchon R, Wenz F, Sauer R. Heart toxicity from breast cancer radiotherapy: current findings, assessment, and prevention. Strahlenther Onkol. 2019;195(1):1–12 The German Society for Radiation Oncology published dose constraints for cardiac substructures based on a literature review of the available data for patients with breast cancer. This is the most updated and comprehensive dose constraints available for cardiac substructures for this patient population.
Hoppe BS, Bates JE, Mendenhall NP, Morris CG, Louis D, Ho MW, Hoppe RT, Shaikh M, Li Z, Flampouri S. The meaningless meaning of mean heart dose in mediastinal lymphoma in the modern radiation therapy era. Pract Radiat Oncol. 2020;10(3):e147–54.
Atkins KM, Bitterman DS, Chaunzwa TL, Kozono DE, Baldini EH, Aerts HJWL, Tamarappoo BK, Hoffmann U, Nohria A, Mak RH. Mean heart dose is an inadequate surrogate for left anterior descending coronary artery dose and the risk of major adverse cardiac events in lung cancer radiation therapy. Int J Radiat Oncol Biol Phys. 2021;110(5):1473–9.
Finnegan R, Lorenzen EL, Dowling J, Jensen I, Berg M, Thomsen MS, Delaney GP, Koh ES, Thwaites D, Brink C, Offersen BV, Holloway L. Analysis of cardiac substructure dose in a large, multi-centre danish breast cancer cohort (the DBCG HYPO trial): trends and predictive modelling. Radiother Oncol. 2020;153:130–8.
CAS PubMed Article Google Scholar
Jacob S, Camilleri J, Derreumaux S, Walker V, Lairez O, Lapeyre M, Bruguière E, Pathak A, Bernier MO, Laurier D, Ferrieres J, Gallocher O, Latorzeff I, Pinel B, Franck D, Chevelle C, Jimenez G, Broggio D. Is mean heart dose a relevant surrogate parameter of left ventricle and coronary arteries exposure during breast cancer radiotherapy: a dosimetric evaluation based on individually-determined radiation dose (BACCARAT study). Radiat Oncol. 2019;14(1):29.
PubMed PubMed Central Article Google Scholar
Taylor CW, Nisbet A, McGale P, Goldman U, Darby SC, Hall P, Gagliardi G. Cardiac doses from Swedish breast cancer radiotherapy since the 1950s. Radiother Oncol. 2009;90(1):127–35.
Taylor CW, Brønnum D, Darby SC, Gagliardi G, Hall P, Jensen MB, McGale P, Nisbet A, Ewertz M. Cardiac dose estimates from Danish and Swedish breast cancer radiotherapy during 1977-2001. Radiother Oncol. 2011;100(2):176–83.
PubMed PubMed Central Article Google Scholar
van Velzen SGM, Gal R, Teske AJ, van der Leij F, van den Bongard DHJG, Viergever MA, Verkooijen HM, Išgum I. AI-based radiation dose quantification for estimation of heart disease risk in breast cancer survivors after radiation therapy. Int J Radiat Oncol Biol Phys. 2022;112(3):621–32.
留言 (0)